FDA Updates Depo-Provera Label to Include Brain Tumor Risk — Key Litigation Development

The U.S. Food and Drug Administration (FDA) has approved a significant update to the prescribing information for Depo-Provera, adding a warning about a potential association with meningiomas, a type of brain tumor. This marks a significant shift in regulatory guidance for the long-acting injectable contraceptive, which has been under increasing scientific and legal scrutiny in recent years….
By: Morris James LLP